The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated massive profits, the end of its patent opened the avenue to off-brand alternatives, https://mysocialguides.com/story7147467/the-copyright-and-big-pharma-a-volatile-investment